Search
Rhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingGI-5005
go.drugbank.com/drugs/DB05942InvestigationalGI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. … GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection.
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Avena sativa flowering top
go.drugbank.com/drugs/DB14253ApprovedAvena sativa flowering top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
CG7870
go.drugbank.com/drugs/DB04981InvestigationalCG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Tocopherylquinone
go.drugbank.com/drugs/DB14094InvestigationalCategories: Compounds used in a research, industrial, or household settingMorin
go.drugbank.com/drugs/DB16770ExperimentalSynonyms: Al-MorinCategories: Compounds used in a research, industrial, or household setting3,4-Dihydroxybenzoic Acid
go.drugbank.com/drugs/DB03946ExperimentalCategories: Compounds used in a research, industrial, or household settingAnpocogin
go.drugbank.com/drugs/DB06552InvestigationalRecombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity. [A175642]
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who